Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high ...

A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an ...

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted ...

A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor ...

Biomarker-driven drug development is accelerating across oncology as companies advance novel mechanisms targeting previously ...

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

BERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic ...

FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data ...

Targeted drug delivery is a powerful and promising area of medicine. Therapies that pinpoint the exact areas of the body ...

Targeted drug delivery is a powerful and promising area of medicine. Therapies that pinpoint the exact areas of the body ...